newsfilter
← Latest News
GlobeNewswire·

Galecto Reports Third Quarter 2024 Financial Results

- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge